53% Of Blood Cancer Treated With CAR-T Cell Immunotherapy Healed

Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year.

The treatment, liso-cel, is a newer type of immunotherapy known as CAR-T cell therapy, that takes immune cells from a patient, engineers them to better recognize and attack cancer and infuses them back into the patient.

The study tested three dose levels of liso-cel in the 269 patients with relapsed or refractory large B-cell lymphoma. Nearly three quarters of the patients responded to the one-time treatment, with 53% experiencing a complete response, meaning no detectable sign of the cancer, according to data presented at American Society of Hematology Conference in Orlando.

The data marks a win for Bristol-Myers after its purchase of Celgene met resistance from some investors who thought that it was overpaying for the cancer-focused biotech. It is also a positive sign for Celgene investors, who are entitled to received a contingent value right, or CVR, payment of $9 a share if three treatments in development, including liso-cel, achieve timely approvals.

Source: https://www.reuters.com/